Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Open Label, Phase 1a, Dose-Escalation Study Evaluating the Safety of Fractionated MNPR-101-PCTA-177Lu Dosing in the Treatment of Solid Tumor Cancers

NCT06617169 is registered in ClinicalTrials.gov with Monopar Therapeutics as lead sponsor.

NCT NCT06617169
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06617169 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Open Label, Phase 1a, Dose-Escalation Study Evaluating the Safety of Fractionated MNPR-101-PCTA-177Lu Dosing in the Treatment of Solid Tumor Cancers
Lead sponsor
Monopar Therapeutics
Phase
Phase 1
Overall status
Active, not recruiting
Start date
October 8, 2024
Completion date
February 28, 2027
Enrollment
12 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

bladder cancer, colorectal cancer, gastric cancer, lung cancer, ovarian cancer, pancreatic cancer, solid tumor, adult, triple-negative breast cancer, urothelial carcinoma